Mor A, Nicolas P
Laboratoire de Bioactivation des Peptides, Insitut Jacques Monod, Paris, France.
J Biol Chem. 1994 Jan 21;269(3):1934-9.
Dermaseptin, a 34-amino acid residue cationic peptide, was recently shown to inhibit the growth of pathogenic fungi responsible for severe opportunistic infections accompanying immunodeficiency syndrome and the use of immunosuppressive agents. To improve our understanding of the mechanism by which dermaseptin exerts its potent antimicrobial action, a series of either NH2- or COOH-terminally truncated analogs was synthesized. These analogs were evaluated for their ability to inhibit the growth of various pathogenic agents in culture medium. Dermaseptin exerted a lytic action upon bacteria, protozoa, yeasts, and filamentous fungi at micromolar concentrations. No inhibition of proliferation was observed with human KB cells, and dermaseptin did not lyse guinea pig lymphocytes or rabbit erythrocytes at doses up to 200 micrograms/ml. Shortening the peptide chain of dermaseptin to dermaseptin-(3-34) slightly reduced the activity of the peptide, while further reduction of the chain length to residues 14-34, 16-34, 20-34, and 28-34 yielded peptide derivatives devoid of antimicrobial activity. On the other hand, lengthening the peptide chain starting from residues 1-4 to residues 1-8 and 1-18 led to a progressive recovery of the activity of the parent molecule. Whereas the central core of dermaseptin (residues 10-19) was virtually inactive, alteration of the COOH-terminal carboxylic group of dermaseptin-(1-18) to a carboxamide yielded a peptide exhibiting enhanced antimicrobial potency, yet displaying even less in vitro toxicity compared with dermaseptin. Overall, the data indicate that molecular elements responsible for the exceptional antimicrobial potency of dermaseptin are to be traced to the NH2-terminal alpha-helical amphipathic segment spanning residues 1-18 of the molecule. Dermaseptin-(1-18)-NH2 may therefore be considered as a useful and highly tractable tool for identifying key features responsible for membrane permeabilization and as a starting point for the design of new therapeutic agents.
皮肤防御素是一种由34个氨基酸残基组成的阳离子肽,最近研究表明它能抑制导致免疫缺陷综合征和使用免疫抑制剂后严重机会性感染的致病真菌的生长。为了更好地理解皮肤防御素发挥其强大抗菌作用的机制,合成了一系列氨基端或羧基端截短的类似物。评估了这些类似物在培养基中抑制各种病原体生长的能力。皮肤防御素在微摩尔浓度下对细菌、原生动物、酵母和丝状真菌具有裂解作用。在人KB细胞中未观察到增殖抑制,并且在高达200微克/毫升的剂量下,皮肤防御素不会裂解豚鼠淋巴细胞或兔红细胞。将皮肤防御素的肽链缩短为皮肤防御素-(3-34)会稍微降低该肽的活性,而进一步将链长缩短至残基14-34、16-34、20-34和28-34则产生了没有抗菌活性的肽衍生物。另一方面,从残基1-4开始将肽链延长至残基1-8和1-18导致母体分子的活性逐渐恢复。虽然皮肤防御素的中央核心(残基10-19)几乎没有活性,但将皮肤防御素-(1-18)的羧基末端羧基改变为羧酰胺产生了一种抗菌效力增强的肽,并且与皮肤防御素相比在体外毒性更小。总体而言,数据表明负责皮肤防御素非凡抗菌效力的分子元件可追溯到分子中跨越残基1-18的氨基端α-螺旋两亲性片段。因此,皮肤防御素-(1-18)-NH2可被视为一种有用且易于处理的工具,用于识别负责膜通透化的关键特征,并作为设计新治疗剂的起点。